New antithrombotic drugs in development;Neue antithrombotische Medikamente

Internist

Volumn 38, Issue 7, 1997, Pages 680-687

  Greinacher, A ^a,b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Inst F Immunol T   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; DANAPAROID; DERMATAN SULFATE; EFEGATRAN; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRUDIN; HIRULOG; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RIDOGREL; TICLOPIDINE; TIROFIBAN;

DRUG DEVELOPMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 84866471680     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050080     Document Type: Review

References (41)

1. Antiplatelet therapy trialists collaborators (1994) Collaborative overview of randomised trials of antiplatelet therapy-1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106
2. Antman EM (1994) Hirudin in acute myocardial-infarction-safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9a trial. Circulation 90:1624-1630
3. Antman EM (1996) Hirudin in acute myocardial infarction: Thrombolysis and thrombin Inhibition in myocardial infarction (TIMI) 9b trial. Circulation 94:911-921
4. Boneu B (1996) Glycosaminoglycans: Clinical use. Semin Thromb Hemost 22:209-212
5. Boneu B, Necciari, J, Cariou R, Sie P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani M (1995) Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemos 74:1467-1473
6. Breddin HK (1997) Heparinoids. Hämostaseologie 17:49-53
7. Callas DD, Hoppensteadt D, Fareed J (1995) Comparative Studie on the anticoagulant and protease generation inhibitory action of newly developed site-directed thrombin inhibitory drugs. Semin Thromb Hemos 21:177-183
8. Caprie Steering Commitee (1996) A randomised, blinded, trial of clopidogrel versus aspiring in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
9. de Valk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJAT, Hart HC, Sixma JJ, Nieuwenhuis HK (1995) Comparing subcutaneous danaparoid with intravenous unfractioned heparin for the treatment of venous thromboembolism. A randomized controlled trial Am Intern Med 123:1-9
10. Eriksson BI, Ekman S, Kalebo O, Zachrisson B, Bach D, Close P (1996) Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 347:635-639
11. Fareed J, Callas DD (1995) Pharmacological aspects of thrombin inhibitors: a developmental perspective. Vessels 1:15-24
12. Greinacher A (1996) Heparin-induzierte Thrombozytopenien. Internist 37:1172-1178
13. Greinacher A, Alban S (1996) Heparinoide als eine Alternative für die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie. Hämostaseologie 16:41-49
14. Greinacher A, Völpel H, Pötzsch B (1996) Recombinant hirudin in the treatment of patients with Heparin-induced thrombocytopenia. Blood 88:1113 (Abstract)
15. Jackson CV, Satterwhite J, Roberts E (1996) Preclinical and clinical pharmacology of Efegatran (LY224468): A Novel antithrombin for the treatment of acute coronary syndromes. Clin Appl Thromb/Hemos 2:258-267
16. Jeske W, Hoppensteadt D, Callas D, Koza MJ, Fareed J (1996) Pharmacological profiling of recombinant tissue-factor-pathway inhibitor. Semin Thromb Hemos 22:213-219
17. Koopman MPW, Prandoni P, Piovella F, Ockelford PA, Bandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman cH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d'Azemar P, Büller HR (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334:682-687
18. Lefkovits J, Ivanhoe RJ, Califf RM et al. For te EPIC investigators (1996) Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 77:1045-1051
19. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deepp-vein thrombosis. N Engl J. Med 334:677-681
20. Markwardt F (1994) The development of hirudin as an antithrombotic drug. Thromb Res 71:1-23
21. Markwardt F (1996) Antithrombotic agents from hematophagous animals. Clin Appl Thromb/Hemos 2:75-82
22. Mills DCB (1996) ADP receptors on platelets. Thromb Haemos 76:835-856
23. Neuhaus KL, Vonessen R, Teube U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T (1994) Safety observations from improvement of thrombolysis (HIT III) study - a study of the Arbeitsgemeinschaft-leitender-kardiologischer-Krankenhausaertze (alkk). Circulation 90:1638-1642
24. Nowak G, Bucha E (1996) Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemos 22:197-202
25. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G (1997) The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardiopulmonary bypass. Thromb Haemos in press
26. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084-1089
27. Schrör K (1995) Antiplatelet Drugs Drugs 50:7-28
28. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Brau PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt mM, Gerstenblith G (1996) Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. Circulation 94:2083-2089
29. Seiler S (1996) Thrombin receptor antagonists. Semin Thromb Hemos 22:223-232
30. The EPIC investigators (1994) Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa in high-risk coronary angioplasty. N Engl J Med 330:956-961
31. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators (1994) A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631-1637
32. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 774:775-782
33. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction: the Ridogrel versus Aspirin Patency Trial (RAPT). Circulation 89:588-595
34. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, on Behalf of the Investigators (1996) Platelet Membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. Circulation 94:899-905
35. Topol EJ (1995) Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J 130:666-672
36. Topol EJ, Califf RM, Weisman HF et al. on behalf of the EPIC Investigators (1994) Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for months. Lancet 343:881-886
37. Turpie AGG (1992) Orgaran in the prevention of deep-vein thrombosis in stroke patients. Haemostasis 22:91-98
38. Vermylen J, Verhaeghe R (1997) New platelet aggregation inhibitors. Hämostaseologie 17:43-48
39. Verstraete JM, Zoldhelyi P (1996) Novel antithrombotic drugs in development. Drugs 49:856-884
40. Wallis RB (1996) Hirudins: from leeches to man. Semin Thromb Hemos 22:185-196
41. Weitz JI, Huboda M, Massel D, Marganore, J, Hirsh J (1990) Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 86:385-391